High-sensitivity C-reactive Protein Level in Stable-state Bronchiectasis Predicts Exacerbation Risk

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2024 Feb 13

PMID 38350918

Authors

Wang Chun Kwok

Kay Cheong Teo

Kui Kai Lau

James Chung-Man Ho

Affiliations

Soon will be listed here.

Abstract

Background: Elevation of systemic inflammatory markers were found to correlate with increased disease extent, reduced lung function and higher risk of future severe exacerbations in patients with bronchiectasis. Although a significant correlation of circulating hs-CRP levels with HRCT scores and resting oxygen saturation in patients with stable-state non-cystic fibrosis (CF) bronchiectasis was suggested, there is little data on the relationship between hs-CRP and the prognosis of bronchiectasis and a lack of data on the role of hs-CRP in predicting bronchiectasis exacerbation.

Methods: A prospective study was conducted on Chinese patients with non- CF bronchiectasis from 1st October to 31st December 2021. Baseline serum hs-CRP were obtained at stable-state. The follow-up period lasted for one year. Co-primary endpoints were the development of any bronchiectasis exacerbation and hospitalized bronchiectasis exacerbation.

Results: Totally 123 patients were included. Higher hs-CRP was associated with increased risk to develop any bronchiectasis exacerbation, adjusted odds ratio (aOR) of 2.254 (95% CI = 1.040-4.885, p = 0.039), and borderline significantly increased hospitalized bronchiectasis exacerbation with aOR of 1.985 (95% CI = 0.922-4.277, p = 0.080).

Conclusion: Baseline serum hs-CRP level at stable-state can predict risk of bronchiectasis exacerbation, which is reflecting chronic low-grade inflammation in bronchiectasis.

Citing Articles

Bronchiectasis Exacerbation Increases the Risk of Adverse Renal Outcomes-Results From a Large Territory-Wide Cohort Study.

Kwok W, Tsui C, Sze Him Isaac L, Wong C, Tam T, Man Ho J Clin Respir J. 2025; 19(1):e70029.

PMID: 39797651 PMC: 11724331. DOI: 10.1111/crj.70029.

Epidemiology of bronchiectasis at a single center in Japan: a retrospective cohort study.

Hashimoto K, Abe Y, Fukushima K, Niitsu T, Komukai S, Miyamoto S BMC Pulm Med. 2024; 24(1):531.

PMID: 39448945 PMC: 11520111. DOI: 10.1186/s12890-024-03337-7.

The Association Between Systemic Immune-Inflammation Index at Admission and Readmission in Patients with Bronchiectasis.

Gao F, He S, Li J, Wang X, Chen X, Bu X J Inflamm Res. 2024; 17:6051-6061.

PMID: 39247843 PMC: 11380867. DOI: 10.2147/JIR.S479214.

Exacerbations of bronchiectasis.

De Angelis A, Johnson E, Sutharsan S, Aliberti S Eur Respir Rev. 2024; 33(173).

PMID: 39048130 PMC: 11267293. DOI: 10.1183/16000617.0085-2024.

References

Wilson C, Jones P, OLeary C, Hansell D, Dowling R, COLE P . Systemic markers of inflammation in stable bronchiectasis. Eur Respir J. 1998; 12(4):820-4. DOI: 10.1183/09031936.98.12040820. View

Kapur N, Masters I, Chang A . Longitudinal growth and lung function in pediatric non-cystic fibrosis bronchiectasis: what influences lung function stability?. Chest. 2010; 138(1):158-64. DOI: 10.1378/chest.09-2932. View

Posadas T, Oscullo G, Zaldivar E, Villa C, Dobarganes Y, Giron R . C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). Arch Bronconeumol (Engl Ed). 2020; 57(1):21-27. DOI: 10.1016/j.arbres.2019.12.017. View

Ho P, Chan K, Ip M, Lam W, Ho C, Yuen K . The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest. 1999; 114(6):1594-8. DOI: 10.1378/chest.114.6.1594. View

Boyton R, Altmann D . Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology. Annu Rev Pathol. 2016; 11:523-54. DOI: 10.1146/annurev-pathol-012615-044344. View

Sheehan R, Wells A, Copley S, Desai S, Howling S, COLE P . A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J. 2002; 20(3):581-7. DOI: 10.1183/09031936.02.00284602. View

Niyi-Odumosu F, Bello O, Biliaminu S, Owoyele B, Abu T, Dominic O . Resting Serum Concentration of High-Sensitivity C-Reactive Protein (hs-CRP) in Sportsmen and Untrained Male Adults. Niger J Physiol Sci. 2017; 31(2):177-181. View

Hill A, Haworth C, Aliberti S, Barker A, Blasi F, Boersma W . Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.00051-2017. View

Shoemark A, Cant E, Carreto L, Smith A, Oriano M, Keir H . A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. Eur Respir J. 2019; 53(6). DOI: 10.1183/13993003.00303-2019. View

10.

Martinez-Garcia M, Athanazio R, Giron R, Maiz-Carro L, de la Rosa D, Olveira C . Predicting high risk of exacerbations in bronchiectasis: the E-FACED score. Int J Chron Obstruct Pulmon Dis. 2017; 12:275-284. PMC: 5279836. DOI: 10.2147/COPD.S121943. View

11.

Kaplan M . Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol. 2009; 5(4):208-17. DOI: 10.1038/nrrheum.2009.29. View

12.

Yeh E, Willerson J . Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003; 107(3):370-1. DOI: 10.1161/01.cir.0000053731.05365.5a. View

13.

Bower J, Lazo M, Juraschek S, Selvin E . Within-person variability in high-sensitivity C-reactive protein. Arch Intern Med. 2012; 172(19):1519-21. PMC: 3613132. DOI: 10.1001/archinternmed.2012.3712. View

14.

Hsieh M, Fang Y, Chen G, Chung F, Liu Y, Wu C . The role of the high-sensitivity C-reactive protein in patients with stable non-cystic fibrosis bronchiectasis. Pulm Med. 2014; 2013:795140. PMC: 3870862. DOI: 10.1155/2013/795140. View

15.

Cesari M, Penninx B, Newman A, Kritchevsky S, Nicklas B, Sutton-Tyrrell K . Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003; 108(19):2317-22. DOI: 10.1161/01.CIR.0000097109.90783.FC. View

16.

McDonnell M, Aliberti S, Goeminne P, Restrepo M, Finch S, Pesci A . Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016; 4(12):969-979. PMC: 5369638. DOI: 10.1016/S2213-2600(16)30320-4. View

17.

Liu A, Lv H, Tan B, Shu H, Yang H, Li J . Accuracy of the highly sensitive C-reactive protein/albumin ratio to determine disease activity in inflammatory bowel disease. Medicine (Baltimore). 2021; 100(14):e25200. PMC: 8036110. DOI: 10.1097/MD.0000000000025200. View

18.

Chalmers J, Smith M, McHugh B, Doherty C, Govan J, Hill A . Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012; 186(7):657-65. DOI: 10.1164/rccm.201203-0487OC. View

19.

Parnham M, Erakovic Haber V, Giamarellos-Bourboulis E, Perletti G, Verleden G, Vos R . Azithromycin: mechanisms of action and their relevance for clinical applications. Pharmacol Ther. 2014; 143(2):225-45. DOI: 10.1016/j.pharmthera.2014.03.003. View

20.

Polverino E, Goeminne P, McDonnell M, Aliberti S, Marshall S, Loebinger M . European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.00629-2017. View